Literature DB >> 2510288

Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man.

I Bjarnason1, P Smethurst, P Clark, I Menzies, J Levi, T Peters.   

Abstract

This study examines whether NSAID induced disruption of small intestinal integrity is preventable by concomitant prostaglandin administration, and whether prostaglandins themselves interfere with intestinal permeability and absorption. Twelve subjects underwent testing following treatment as indicated: baseline, no treatment rioprostil, 300 micrograms, at -9 and -1 h indomethacin, 75 mg and 50 mg, at -9 and -1 h respectively rioprostil plus indomethacin, regimen as above. At 0800 h (0 h) subjects drink a solution containing 51CrEDTA 100 microCi, L-rhamnose 0.5 g, D-xylose 0.5 g and 3-O-methyl-glucose 0.2 g; this is followed by a 5-h urine collection. The amount of test substance in the urine reflects non-mediated intercellular and transcellular permeability, and passive and active carrier mediated transport systems, respectively. Permeation of L-rhamnose, D-xylose and 3-O-methyl-glucose is unaffected by rioprostil and/or indomethacin. Indomethacin significantly increases intestinal permeability to 51CrEDTA; coadministration of rioprostil, however, significantly decreases this detrimental effect of indomethacin. These findings suggest that prostaglandins are essential for maintaining small intestinal integrity in man and lend further support to the suggestion that NSAIDs damage the small intestine by reducing mucosal prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510288     DOI: 10.3109/00365528909091195

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  NSAID enteropathy: could probiotics prevent it?

Authors:  Massimo Montalto; Antonella Gallo; Antonio Gasbarrini; Raffaele Landolfi
Journal:  J Gastroenterol       Date:  2012-08-09       Impact factor: 7.527

Review 2.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

Review 3.  Intestinal epithelial function: the case for immunophysiological regulation. Implications for disease (2).

Authors:  D M McKay; M H Perdue
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

Review 4.  Intestinal permeability.

Authors:  I Bjarnason
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

5.  COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.

Authors:  G Sigthorsson; R Crane; T Simon; M Hoover; H Quan; J Bolognese; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor.

Authors:  F Mion; J C Cuber; Y Minaire; J A Chayvialle
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

Review 7.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

8.  Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability.

Authors:  G R Davies; M E Wilkie; D S Rampton
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.